Table 2.

Prediction accuracy (%)^d of 21 N-glycan biomarkers for RF-negative and/or ACPA-negative patients

N-Glycan biomarkers	Training set			Validation set
	R(−)a patients (n = 19)	A(−)b patients (n = 15)	R&A(−)c patients (n = 8)	R(−)a patients (n = 97)	A(−)b patients (n = 55)	R&A(−)c patients (n = 45)
Neutral N-glycans
5_3_1_0-b	95	93	100	88	91	96
6_3_1_0-b	100	100	100	77	82	80
6_3_1_0-a	95	93	100	72	69	76
3_5_0_0-c	100	100	100	79	82	82
5_5_0_0-b	89	93	100	66	60	60
5_3_1_0-c	95	93	100	77	87	91
3_3_0_0-a	95	93	100	71	58	64
4_3_1_0-b	95	93	100	69	58	64
4_2_0_0	63	53	50	82	95	93
Acidic N-glycans
8_6_1_2	89	87	75	80	75	78
4_3_1_1-a	95	93	88	75	75	76
4_3_0_1-c	89	93	88	78	82	84
5_5_0_2-b	100	100	100	71	65	76
6_5_0_2	89	93	88	72	73	76
7_5_1_1-b	89	87	75	77	78	82
5_4_0_1-a	100	100	100	59	51	60
4_4_1_1-a	89	87	88	59	51	60
Sulfated N-glycans
5_4_1_1 + SO3-b (SGm2)	95	93	88	84	82	82
4_3_1_1 + SO3-b (SGm1)	100	100	100	76	78	73
5_4_1_2 + SO3-b	95	93	100	64	51	60
5_4_0_1 + SO3-a	84	80	88	70	82	82
All	89	87	100	81	80	80
SGm1 and SGm2	95	93	95	87	85	84

^aR(−) represented RF-negative RA patients

^bA(−) represented ACPA-negative RA patients

^cR&A(−) represented RF&ACPA-negative RA patients

^dThe prediction accuracy refers to the ratio of the number of samples correctly predicted as RA to the total number of samples actually diagnosed as RA in corresponding subsets using the regular diagnostic methods